1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
ViraCyte, LLC is a company with 1 orphan drug designation across 3 rare diseases. 6 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cytomegalovirus infection | cytomegalovirus specific cytotoxic T lymphocytes | Des.TrialAppr. |
| fetal cytomegalovirus syndrome | cytomegalovirus specific cytotoxic T lymphocytes | Des.TrialAppr. |
| idiopathic disseminated cytomegalovirus infection | cytomegalovirus specific cytotoxic T lymphocytes | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
6
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
6
affecting portfolio